Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.
Acura Pharmaceuticals re-acquires rights to its AVERSION Technology from Pfizer
M2 - Thu Apr 10, 5:46AM CDT
Pharmaceutical company Acura Pharmaceuticals (NASDAQ:ACUR) disclosed on Thursday the termination of the license of its AVERSION Technology to Pfizer.
Acura Pharmaceuticals Announces Return of Product Rights
Marketwire - Thu Apr 10, 5:15AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERSION(R) Technology and the return to Acura of the FDA approved Oxecta(R) (oxycodone HCl) product. The letter agreement provides that Acura will make a one-time payment of $2.0 million to Pfizer. The license termination is effective April 9, 2014. The AVERSION(R) Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Faruqi & Faruqi, LLP Launches An Investigation Against Acura Pharmaceuticals, Inc. (ACUR) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Thu Mar 20, 1:56PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Acura Pharmaceuticals, Inc. ("Acura" or the "Company"
Acura Pharmaceuticals, Inc. (ACUR) in Focus: Stock Moves 7.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:44AM CDT
Acura Pharmaceuticals, Inc. (ACUR) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 1:00PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
Stock to Watch: Acura Pharmaceuticals Down 9.6% (ACUR)
Comtex SmarTrend(R) - Tue Mar 04, 10:12AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's worst performing low-priced stocks, down 9.6% to $1.78 on 2.2x average daily volume. Thus far today, Acura Pharmaceuticals has traded 736,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's 1.2%) and underperformed the S&P 500 (-9.6% to the S&P's 1.3%) during today's trading.
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Mon Mar 03, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.
Acura Pharmaceuticals Up 6.2%, Shares Break Through Resistance (ACUR)
Comtex SmarTrend(R) - Thu Feb 27, 11:40AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 6.2% to $2.06 on 3.4x average daily volume. Acura Pharmaceuticals has traded 972,000 shares thus far today, vs. average volume of 285,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
Acura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Marketwire - Tue Feb 18, 3:05PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3, 2014. The Company will host a conference call to discuss the results on Tuesday, March 4, 2014 at 8:30 a.m. ET.
Stock to Watch: Acura Pharmaceuticals Up 8.6% (ACUR)
Comtex SmarTrend(R) - Tue Feb 18, 10:11AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 8.6% to $2.01 on 5.5x average daily volume. Acura Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 208,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.1%) and outperformed the S&P 500 (8.6% to the S&P's 0.1%) during today's trading.
Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 7:44AM CST
Acura Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise 5% on the day.
Traders Get Bullish on Shares of Acura Pharmaceuticals, Shares Up 5.7% (ACUR)
Comtex SmarTrend(R) - Fri Feb 14, 10:41AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 5.7% to $1.86 on 3.5x average daily volume. Acura Pharmaceuticals has traded 736,000 shares thus far today, vs. average volume of 210,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.4%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.
4 Stocks Under $10 Moving Higher
at The Street - Fri Feb 14, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Acura Confirms $10M Loan Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 6:05PM CST
Acura confirmed a $10 million debt financing from Oxford Finance.
Acura Pharmaceuticals secures USD10m term loan from Oxford Financing
M2 - Tue Dec 31, 6:07AM CST
Specialty pharmaceutical company Acura Pharmaceuticals Inc (Nasdaq:ACUR) announced on Monday that it has entered into a loan and security agreement with Oxford Finance LLC, under which Oxford has agreed to make a term loan to the company of USD10m in principal amount.
Acura Pharmaceuticals Secures $10.0 Million of Debt Financing
Marketwire - Mon Dec 30, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) entered into a Loan and Security Agreement (the "Loan Agreement"
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
Acura Pharma and FDA discuss anti-abuse pain pill
AP - Mon Dec 09, 12:22PM CST
WASHINGTON (AP) — Shares of Acura Pharmaceuticals Inc. rose Monday after the company said it met with federal regulators to discuss a new version of the painkiller hydrocodone that uses the company's abuse-resistant technology.